The PRMT5 inhibitor LLY-283 combined with FLT3 TKIs showed synergistically enhanced inhibition of FLT3-ITD + AML cell lines compared to TKIs or PRMT5 inhibitor alone, warranting further investigation [145, 146]. This evidence concerns the gene FLT3 and acute myeloid leukemia.